Keros Therapeutics (KROS) Set to Announce Quarterly Earnings on Wednesday

Keros Therapeutics (NASDAQ:KROS) is expected to issue its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Keros Therapeutics to post earnings of ($0.96) per share and revenue of $14.76 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:00 PM ET.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Monday, August 3rd. The company reported ($1.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.11). On average, analysts expect Keros Therapeutics to post ($5.27) EPS for the current fiscal year and ($6.39) EPS for the next fiscal year.

Keros Therapeutics Price Performance

NASDAQ:KROS opened at $11.26 on Wednesday. The company’s 50 day moving average is $11.25 and its two-hundred day moving average is $12.26. Keros Therapeutics has a twelve month low of $9.69 and a twelve month high of $22.55.

Keros Therapeutics declared that its Board of Directors has authorized a stock buyback plan on Wednesday, September 9th that allows the company to repurchase $5 million in outstanding shares. This repurchase authorization allows the company to buy up to 2.3% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board of directors believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Zacks Research raised Keros Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 27th. Leerink Partners reduced their price target on Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 4th. Wells Fargo & Company reduced their price objective on shares of Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating for the company in a research report on Tuesday, August 4th. Wall Street Zen lowered Keros Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Keros Therapeutics in a research report on Wednesday, August 12th. Four research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Keros Therapeutics presently has an average rating of “Hold” and an average price target of $20.50.

Insiders Place Their Bets

In related news, insider Lorena Raquel Lerner sold 3,568 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $10.29, for a total value of $36,714.72. Following the completion of the transaction, the insider owned 27,559 shares of the company’s stock, valued at approximately $283,582.11. This represents a 11.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 5,343 shares of company stock worth $54,985. 12.60% of the stock is currently owned by company insiders.

About Keros Therapeutics

Keros Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for diseases caused by dysfunctional signaling in the transforming growth factor-beta (TGF-β) superfamily of proteins. The company uses its research platform to design therapies intended to regulate signaling pathways involved in blood-cell production, bone health and cardiovascular function.

Keros’ investigational pipeline has included elritercept (KER-050), an activin receptor type IIA ligand trap being studied for hematologic conditions such as lower-risk myelodysplastic syndromes and myelofibrosis.